Mycobacterial Antigens Exacerbate Disease Manifestations in Mycobacterium tuberculosis-Infected Mice

ABSTRACT To control tuberculosis worldwide, the burden of adult pulmonary disease must be reduced. Although widely used, Mycobacterium bovis BCG vaccination given at birth does not protect against adult pulmonary disease. Therefore, postexposure vaccination of adults with mycobacterial antigens is being considered. We examined the effect of various mycobacterial antigens on mice with prior M. tuberculosis infection. Subcutaneous administration of live or heat-treated BCG with or without lipid adjuvants to infected mice induced increased antigen-specific T-cell proliferation but did not reduce the bacterial load in the lungs and caused larger lung granulomas. Similarly, additional mycobacterial antigen delivered directly to the lungs by aerosol infection with viable M. tuberculosis mixed with heat-killed Mycobacterium tuberculosis (1:1) also did not reduce the bacillary load but caused increased expression of tumor necrosis factor alpha (TNF-α) and interleukin 6 (IL-6), which was associated with larger granulomas in the lungs. When M. tuberculosis-infected mice were treated with recombinant BCG that secreted cytokines shown to reduce disease in a preinfection vaccine model, the BCG secreting TNF-α, and to a lesser extent, IL-2 and gamma interferon (IFN-γ), caused a significant increase in granuloma size in the lungs. Moreover, treatment of M. tuberculosis-infected mice with recombinant murine TNF-α resulted in increased inflammation in the lungs and accelerated mortality without affecting the bacillary load. Taken together, these studies suggest that administration of mycobacterial antigens to mice with prior M. tuberculosis infection leads to immune activation that may exacerbate lung pathology via TNF-α-induced inflammation without reducing the bacillary load.

[1]  Gilla Kaplan,et al.  Immunopathologic Effects of Tumor Necrosis Factor Alpha in Murine Mycobacterial Infection Are Dose Dependent , 2000, Infection and Immunity.

[2]  J. Glassroth,et al.  Clinical considerations in designing trials of vaccines for tuberculosis. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  I. Orme,et al.  Effective Preexposure Tuberculosis Vaccines Fail To Protect When They Are Given in an Immunotherapeutic Mode , 2000, Infection and Immunity.

[4]  A. Aderem,et al.  Toll-like receptor-2 mediates mycobacteria-induced proinflammatory signaling in macrophages. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[5]  A. Aderem,et al.  The Toll-like receptor 2 is recruited to macrophage phagosomes and discriminates between pathogens , 1999, Nature.

[6]  K. Moelling,et al.  Therapy of tuberculosis in mice by DNA vaccination , 1999, Nature.

[7]  J. Flynn,et al.  Mice deficient in CD4 T cells have only transiently diminished levels of IFN-gamma, yet succumb to tuberculosis. , 1999, Journal of immunology.

[8]  G. Kaplan,et al.  Selective increase in plasma tumor necrosis factor-alpha and concomitant clinical deterioration after initiating therapy in patients with severe tuberculosis. , 1998, The Journal of infectious diseases.

[9]  Alan D. Roberts,et al.  Evaluation of New Vaccines in the Mouse and Guinea Pig Model of Tuberculosis , 1998, Infection and Immunity.

[10]  T. Whittam,et al.  Restricted structural gene polymorphism in the Mycobacterium tuberculosis complex indicates evolutionarily recent global dissemination. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[11]  G. Kaplan,et al.  Aerosol Infection of Mice with Mycobacteria Using a Nose-Only Exposure Device , 1997 .

[12]  G. Kaplan,et al.  Perforin, a cytotoxic molecule which mediates cell necrosis, is not required for the early control of mycobacterial infection in mice , 1997, Infection and immunity.

[13]  Donna L. Montgomery,et al.  Immunogenicity and protective efficacy of a tuberculosis DNA vaccine , 1996, Nature Medicine.

[14]  M. Colston,et al.  Vaccination against tuberculosis by DNA injection , 1996, Nature Medicine.

[15]  N. Maine,et al.  Randomised controlled trial of single BCG, repeated BCG, or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in Malawi , 1996, The Lancet.

[16]  R. Young,et al.  Manipulation and potentiation of antimycobacterial immunity using recombinant bacille Calmette-Guérin strains that secrete cytokines. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[17]  P. E. M. Fine,et al.  Variation in protection by BCG: implications of and for heterologous immunity , 1995, The Lancet.

[18]  I. Orme,et al.  Demonstration of acquired resistance in Bcgr inbred mouse strains infected with a low dose of BCG montreal. , 1984, Clinical and experimental immunology.

[19]  R. Koch I. Weitere Mittheilungen über ein Heilmittel gegen Tuberculose , 1890 .

[20]  A. Lasfar,et al.  Oromucosal interferon therapy: pharmacokinetics and pharmacodynamics. , 1999, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[21]  P. Fine Vaccines, genes and trials. , 1998, Novartis Foundation symposium.

[22]  G. Kaplan,et al.  Effect of cytokine modulation by thalidomide on the granulomatous response in murine tuberculosis. , 1997, Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[23]  G. Kaplan,et al.  rhuIL-2 adjunctive therapy in multidrug resistant tuberculosis: a comparison of two treatment regimens and placebo. , 1997, Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[24]  E. C. Mooney,et al.  The white plague. , 1979, American heritage.